The collaboration brings together Mayo Clinic’s electronic phenotyping algorithm expertise and 2bPrecise’s precision medicine platform, which integrates clinical and genomic information for patient-specific insights. The two organizations will develop genomics-based clinical decision support tools for 2bPrecise to incorporate into its platform.
Under the collaboration, the organizations will address cardiovascular genetic disease by bringing Mayo Clinic’s familial hypercholesterolemia algorithms into the 2bPrecise platform.
“Mayo Clinic has a very robust genomics research discipline,” said Assaf Halevy, founder and CEO of 2bPrecise. “The wealth of both genetic research and clinical data within the clinic is staggering. This is why we are so excited to collaborate with premier organizations like Mayo Clinic to advance genomic science and help make it clinically actionable.”
More articles on health IT:
AMIA targets healthcare professionals in ‘Why Informatics?’ campaign
Ex-employee allegedly steals 15k records from Beverly Hills clinic: 5 things to know
When will AI beat humans? Maybe within 45 years, experts say
